Merit Medical Systems, Inc. $MMSI Stock Sold by Fort Washington Investment Advisors Inc. OH

Key Points

• Fort Washington Investment Advisors cut its Merit Medical Systems stake by 22.3% in the third quarter, selling 106,253 shares and retaining 369,895 shares valued at approximately $31.9 million. Institutional investors collectively own 99.66% of the company.
• Merit Medical reported quarterly EPS of $1.19, exceeding analyst expectations of $0.96, while revenue rose 9.5% year over year to $418.84 million. The company issued fiscal 2026 EPS guidance of $4.25 to $4.35.
• Analysts remain broadly positive, with the stock receiving a “Moderate Buy” consensus rating and an average price target of $100, compared with its reported opening price of $89.57.

Fort Washington Investment Advisors Inc. OH lessened its stake in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 22.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 369,895 shares of the medical instruments supplier's stock after selling 106,253 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 0.62% of Merit Medical Systems worth $31,896,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of MMSI. GAMMA Investing LLC grew its holdings in Merit Medical Systems by 9.2% during the third quarter. GAMMA Investing LLC now owns 3,550 shares of the medical instruments supplier's stock valued at $306,000 after purchasing an additional 300 shares during the period. Farther Finance Advisors LLC increased its position in Merit Medical Systems by 44.0% in the third quarter. Farther Finance Advisors LLC now owns 890 shares of the medical instruments supplier's stock worth $77,000 after buying an additional 272 shares during the last quarter. Congress Asset Management Co. raised its stake in shares of Merit Medical Systems by 6.4% in the third quarter. Congress Asset Management Co. now owns 1,260,675 shares of the medical instruments supplier's stock valued at $108,708,000 after buying an additional 76,338 shares during the period. Moody National Bank Trust Division bought a new stake in shares of Merit Medical Systems in the third quarter valued at $203,000. Finally, QRG Capital Management Inc. lifted its position in shares of Merit Medical Systems by 10.9% during the 2nd quarter. QRG Capital Management Inc. now owns 9,305 shares of the medical instruments supplier's stock valued at $645,000 after buying an additional 917 shares during the last quarter. Hedge funds and other institutional investors own 99.66% of the company's stock.

Merit Medical Systems Stock Up 2.8%

MMSI opened at $89.57 on Friday. Merit Medical Systems, Inc. has a 12 month low of $59.74 and a 12 month high of $94.75. The company has a market cap of $5.35 billion, a PE ratio of 23.75, a price-to-earnings-growth ratio of 2.18 and a beta of 0.51. The company has a current ratio of 4.20, a quick ratio of 2.79 and a debt-to-equity ratio of 0.44. The company has a 50 day moving average of $88.30 and a 200 day moving average of $75.88.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.96 by $0.23. The business had revenue of $418.84 million for the quarter, compared to analysts' expectations of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, sell-side analysts expect that Merit Medical Systems, Inc. will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MMSI. Canaccord Genuity Group increased their price target on Merit Medical Systems from $85.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on Merit Medical Systems from $77.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Bank of America boosted their price objective on Merit Medical Systems from $92.00 to $97.00 and gave the company a "neutral" rating in a research note on Thursday, August 13th. Wells Fargo & Company upped their price objective on shares of Merit Medical Systems from $74.00 to $83.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $101.00 price objective on shares of Merit Medical Systems in a report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $100.00.

About Merit Medical Systems

Merit Medical Systems, Inc is a medical device company that develops, manufactures and markets disposable products used in interventional, diagnostic and therapeutic procedures. Its devices are designed for use by healthcare professionals in areas including cardiology, radiology, oncology, vascular intervention, gastroenterology and other specialty fields.

The company's product portfolio includes devices for accessing the vasculature, controlling and managing fluids, performing biopsies, treating peripheral vascular disease, delivering embolic therapies, and supporting drainage and intervention procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.